Eli Lilly and Company (NYSE:LLY) Trading Down 2.8% - What's Next?

Key Points

• Eli Lilly shares fell 2.8% on Friday, closing at $948.01 after trading as low as $947.51, with volume slightly below average.
• Analysts remain broadly bullish despite the pullback, with several firms raising price targets after Lilly’s strong Q1 results and the stock still carrying a consensus Moderate Buy rating.
• Recent earnings highlighted Lilly’s momentum: Q1 EPS of $8.55 beat estimates, revenue rose 55.5% year over year, and the company reaffirmed strong full-year guidance while continuing to benefit from demand for GLP-1 drugs like Mounjaro.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock price dropped 2.8% during trading on Friday . The company traded as low as $947.51 and last traded at $948.0140. Approximately 3,048,034 shares traded hands during trading, a decline of 5% from the average daily volume of 3,207,355 shares. The stock had previously closed at $974.96.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on Eli Lilly to $900 from $880, signaling continued confidence in the company’s long-term earnings power despite the target still implying downside from recent trading levels.
• Positive Sentiment: Cantor Fitzgerald also lifted its price target after Lilly’s strong Q1 results, reflecting analyst optimism following better-than-expected earnings, revenue growth, and robust demand for GLP-1 drugs.
• Positive Sentiment: News flow around Lilly’s obesity and weight-loss pipeline remains favorable, with reports highlighting expanding market potential for GLP-1 pills and suggesting the category could reach a much larger patient base.
• Positive Sentiment: Coverage following Lilly’s quarterly earnings continued to emphasize the company’s powerful growth profile, including Mounjaro becoming the world’s best-selling drug and management’s raised full-year guidance.
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in Indiana manufacturing sites, which reinforces supply-chain capacity and signals management’s confidence in future demand.
• Neutral Sentiment: Several articles focused on Lilly’s long-term upside, including bullish speculation about whether it could become a $2 trillion healthcare company; these are sentiment-positive but do not add new near-term catalysts. Article Title
• Neutral Sentiment: Shareholder approval of the board and existing governance structure removes an overhang, but is unlikely to be a major stock-moving catalyst on its own.
• Negative Sentiment: One research note and commentary on recent FDA adverse-event reporting suggest some concern around a hepatic-failure report tied to Foundayo, which could add modest regulatory headline risk even if analysts think the market reaction has been overdone.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an "overweight" rating in a research note on Thursday, February 5th. Guggenheim restated a "buy" rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research note on Tuesday. Scotiabank reiterated an "outperform" rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Sanford C. Bernstein reissued an "outperform" rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Finally, CICC Research raised their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 11th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $1,218.33.

Eli Lilly and Company Stock Down 2.8%

The firm has a market capitalization of $892.78 billion, a price-to-earnings ratio of 33.68, a P/E/G ratio of 1.08 and a beta of 0.48. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a fifty day moving average price of $943.90 and a 200 day moving average price of $990.90.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. During the same period last year, the firm posted $3.34 EPS. The business's revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 35.68 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's payout ratio is currently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company during the 4th quarter worth $25,000. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after acquiring an additional 16 shares during the last quarter. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at $30,000. Finally, 10Elms LLP lifted its stake in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after acquiring an additional 10 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.